Heney D, Bailey C C, Lewis I J
Department of Paediatrics, St James's University Hospital, Leeds, UK.
Biomed Pharmacother. 1990;44(4):199-204. doi: 10.1016/0753-3322(90)90024-4.
The success of allogeneic bone marrow transplantation has been restricted by the occurrence of graft-versus-host disease (GVHD). Attempts at prevention and treatment of GVHD have resulted in only a limited improvement and the morbidity and mortality rate remains high. Thalidomide has been known to have immunosuppressive properties for over 20 years, but it has only recently been used in GVHD. Evidence is now accumulating as to its value both in animal models, and in humans where most benefit has been seen in chronic GVHD. We report our experience using thalidomide in GVHD following allogeneic bone marrow transplantation and review the literature.
异基因骨髓移植的成功一直受到移植物抗宿主病（GVHD）发生的限制。预防和治疗GVHD的尝试仅带来了有限的改善，其发病率和死亡率仍然很高。已知沙利度胺具有免疫抑制特性已有20多年，但直到最近才被用于治疗GVHD。目前，关于其在动物模型和人类中的价值的证据正在积累，在慢性GVHD患者中已观察到其最大益处。我们报告了我们在异基因骨髓移植后使用沙利度胺治疗GVHD的经验并对文献进行了综述。
